Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK | Market Cap | 220.48M -39.4% |
| Revenue (ttm) | 76.45M -66.4% |
| Net Income | 106.01M |
| EPS | 4.80 |
| Shares Out | 20.61M |
| PE Ratio | 2.08 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,530 |
| Open | 10.20 |
| Previous Close | 10.30 |
| Day's Range | 10.00 - 10.80 |
| 52-Week Range | 5.42 - 38.10 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 17, 2026 |
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated... [Read more]
Financial Performance
Financial StatementsNews
Xbrane Biopharma AB Earnings Call Transcript: Q1 2026
Ximluci achieved SEK 17.3 million in Q1 revenue and 8% market share in Europe, with ongoing cost reduction efforts amid price competition. Xdivane development is on track, with new financing terms and a potential SEK 10 billion profit sharing over 10 years.
Xbrane Biopharma AB Quarterly report: Q1 2026
Xbrane Biopharma AB has published its Q1 2026 quarterly earnings report on May 5, 2026.
Xbrane Biopharma AB Slides: Q1 2026
Xbrane Biopharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Xbrane Biopharma AB Earnings Call Transcript: Q4 2025
Ximluci saw strong year-over-year growth and profit contribution, but faces increased price pressure and competition in Europe. Cost reduction measures and FDA resubmission are key focuses, while Xdivane development remains on track for a 2027 US launch.
Xbrane Biopharma AB Annual report: Q4 2025
Xbrane Biopharma AB has published its Q4 2025 annual report on February 20, 2026.
Xbrane Biopharma AB Quarterly report: Q4 2025
Xbrane Biopharma AB has published its Q4 2025 quarterly earnings report on February 20, 2026.
Xbrane Biopharma AB Slides: Q4 2025
Xbrane Biopharma AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 20, 2026.
Xbrane Biopharma AB Earnings Call Transcript: Q3 2025
Ximluci maintained stable market share and revenue in Q3, with resumed shipments and a strong cash position following a directed share issue. FDA approval for U.S. launch is delayed, while Xdivane development progresses on track for a 2028 launch.
Xbrane Biopharma AB Quarterly report: Q3 2025
Xbrane Biopharma AB has published its Q3 2025 quarterly earnings report on October 24, 2025.
Xbrane Biopharma AB Slides: Q3 2025
Xbrane Biopharma AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 24, 2025.
Xbrane Biopharma AB Transcript: Investing in Life Science 2025
Biosimilars are gaining market share due to regulatory changes and growing acceptance. Ximluci, a Lucentis biosimilar, is performing well in Europe and preparing for a U.S. launch, while Xdivane, an Opdivo biosimilar, targets a 2029 launch. Recent restructuring and partnerships have improved financial stability and global reach.
Xbrane Biopharma AB Earnings Call Transcript: Q2 2025
Ximluci saw 11% volume growth in Europe in Q2, with U.S. FDA approval for Lucumsi expected in October. Xtovane's clinical trial is underway, and the Alvotech deal improved liquidity and reduced debt. SEK 240 million was raised in a directed share issue.
Xbrane Biopharma AB Quarterly report: Q2 2025
Xbrane Biopharma AB has published its Q2 2025 quarterly earnings report on August 26, 2025.
Xbrane Biopharma AB Slides: Q2 2025
Xbrane Biopharma AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 26, 2025.